ChinaBio Today -- July 29, 2008 -- Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE: 600521) signed an agreement with Merck (NYSE: MRK) to provide an unnamed finished product to the big pharma. The deal represents a move up for Huahai Pharma, which has traditionally provided APIs to western pharmaceutical companies, as well as finished drugs in China. Under the agreement, Huahai Pharma will formulate, produce and package the drug. Merck will distribute the product worldwide. More details...
